MichaelWayneBoyerMD

Pediatric Hematology & Oncology • Salt Lake City, UT

Director Blood and Marrow Transplant University of Utah

Join to view full profile

Dr. Boyer is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Boyer's full profile

Already have an account?

Office
100 N Medical Dr
BMT
Salt Lake City, UT 84113
Phone+1 801-585-3229

Fax+1 801-585-3432

Education & Training

University of MinnesotaFellowship, Pediatric Hematology/Oncology, 1991 - 1995
University of MinnesotaResidency, Pediatrics, 1987 - 1990
Indiana University School of MedicineClass of 1987

Certifications & Licensure

UT State Medical License 2006 - 2026
OH State Medical License 2000 - 2007
GA State Medical License 1995 - 2001
MN State Medical License 1991 - 1996
American Board of Pediatrics Pediatric Hematology-Oncology

Clinical Trials

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) Start of enrollment: 2011 Oct 01
Recruiting
Phase I/II Study of Treg/Tcon Addback to Partially Matched Related Donor Stem Cells With Myeloablative Conditioning and Post-transplant Cyclophosphamide for High Risk Hematologic Malignancies Start of enrollment: 2013 Jul 12
Terminated
Phase 1
Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients Start of enrollment: 2015 Apr 08
Completed
Phase 2

Publications & Presentations

PubMed

Pembrolizumab with platinum-based chemotherapy with or without epacadostat as first-line treatment for metastatic non-small cell lung cancer: a randomized, partially d...
Michael Boyer, Rina Hui, Damien Urban, Philip Clingan, Wu-Chou Su
BMC Cancer. 2024-07-25
1 citations
Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma.
Nicholas J Vogelzang, James J Rusthoven, James Symanowski, Claude Denham, E Kaukel
Journal of Clinical Oncology. 2023-04-20
88 citations
Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial.
Theodore W Laetsch, Shannon L Maude, Susana Rives, Hidefumi Hiramatsu, Henrique Bittencourt
Journal of Clinical Oncology. 2023-03-20

Journal Articles

Genetic Mechanisms of Target Antigen Loss in CAR19 Therapy of Acute Lymphoblastic Leukemia
John E Levine, Muna Qayed, Stephan A Grupp, Eneida R Nemecek, Stella M Davies, Michael R Verneris, Michael Boyer, Jeffrey A Engelman, Nature
Clinical Pharmacology of Tisagenlecleucel in B-cell Acute Lymphoblastic Leukemia
Michael W Boyer, Bruce L Levine, Carl H June, Theodore W Laetsch, Clinical Cancer Research